Compugen

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. It specializes in the research, development, and commercialization of novel therapeutic candidates primarily in the field of cancer immunotherapy. The company's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT, both designed for the treatment of solid tumors. Compugen employs advanced computational methods for drug discovery, utilizing in silico techniques to predict and select promising drug targets, followed by rigorous experimental validation. The company collaborates with major pharmaceutical partners, including Bayer Pharma AG and Bristol-Myers Squibb, to enhance its research and development efforts. Compugen's focus on innovative therapeutic solutions aims to address significant unmet medical needs in oncology, leveraging its unique predictive capabilities and a robust pipeline of early-stage programs targeting immune resistance mechanisms.